Andrew Wilson Clinical Senior Lecturer in Respiratory Health University of East Anglia Norwich and Honorary Consultant Physician in Respiratory Medicine Norfolk and Norwich University

Idiopathic Pulmonary Fibrosis: Co-trimoxazole Therapy Did Not Prevent Disease Progression

MedicalResearch.com Interview with:

Andrew Wilson Clinical Senior Lecturer in Respiratory Health University of East Anglia Norwich and Honorary Consultant Physician in Respiratory Medicine Norfolk and Norwich University

Dr. Wilson

Andrew M. Wilson, MD
Clinical Senior Lecturer in Respiratory Health
University of East Anglia
Norwich and Honorary Consultant Physician in Respiratory Medicine
Norfolk and Norwich University

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: Idiopathic pulmonary fibrosis has a poor prognosis and limited treatment options. Clinical trial evidence suggested a survival benefit for people taking co-trimoxazole and microbiological data suggested that infection was implicated in prognosis. However this large multicentre study did not show that co-trimoxazole had an beneficial effect in terms of time to all-cause mortality, hospitalisation or lung transplant in people with moderate and severe idiopathic pulmonary fibrosis

MedicalResearch.com: What should readers take away from your report?

Response: Co-trimoxazole should not be given on a prophylactic basis with an aim to prevent disease progression.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: Future research is required to explore different subgroups of individuals, for example those with extensive traction bronchiectasis. In addition, there was a suggestion that co-trimoxazole improved cough and further studies would be required before that was confirmed.

MedicalResearch.com: Is there anything else you would like to add? Any disclosures?

Response: Patients should still receive therapeutic antibiotics as required for respiratory tract infection. This was funded by National Institute for Health Research Efficacy and Mechanism Evaluation Programme Grant number 12/206/09

Citation:

Wilson AM, Clark AB, Cahn T, et al. Effect of Co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs Placebo on Death, Lung Transplant, or Hospital Admission in Patients With Moderate and Severe Idiopathic Pulmonary FibrosisThe EME-TIPAC Randomized Clinical TrialJAMA. 2020;324(22):2282–2291. doi:10.1001/jama.2020.22960

 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.